Research Article

Open Access
Antibodies targeting ADAM17 reverse neurite outgrowth inhibition by myelin-associated inhibitors
View ORCID ProfileNayanendu Saha Correspondence email, Eric Chan, Rachelle P Mendoza, Yevgeniy Romin, View ORCID ProfileMurray J Tipping, View ORCID ProfileDimitar B Nikolov Correspondence email
Nayanendu Saha
1Structural Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Roles: Conceptualization, Investigation, Writing—original draft, Writing—review and editing
Eric Chan
2Molecular Cytology Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Roles: Software, Methodology
Rachelle P Mendoza
3Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY, USA
Roles: Software
Yevgeniy Romin
2Molecular Cytology Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Roles: Methodology
Murray J Tipping
2Molecular Cytology Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Roles: Supervision, Methodology
Dimitar B Nikolov
1Structural Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Roles: Software, Formal analysis, Supervision, Funding acquisition, Methodology, Writing—original draft, Writing—review and editing
Published 25 March 2025. DOI: 10.26508/lsa.202403126
Anti-ADAM17 antibodies reverse neurite outgrowth inhibition
Nayanendu Saha, Eric Chan, Rachelle P Mendoza, Yevgeniy Romin, Murray J Tipping, Dimitar B Nikolov
Life Science Alliance Mar 2025, 8 (6) e202403126; DOI: 10.26508/lsa.202403126
In this Issue
Volume 8, No. 6
June 2025
Advertisement
Jump to section
Subjects
Related Articles
- No related articles found.
Cited By...
- No citing articles found.